Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Liver Steatosis NASH Reversal Timeline Weeks To Achieve Normal Liver Fat

Retatrutide provides a promising approach to the retatrutide liver steatosis NASH reversal timeline, with weeks to achieve normal liver fat demonstrated in Phase 2 trials where up to 93% of patients on the 12mg dose reached normal levels (<5%) by week 48.[1][2] This triple agonist achieved dose-dependent liver fat reductions from 51% to 86%, with most changes occurring in the first 24 weeks, far surpassing placebo.[1][2] These findings highlight retatrutide's potential to accelerate fatty liver disease and NASH reversal compared to lifestyle interventions alone.[4]

What Is Retatrutide and How Does It Target Liver Steatosis and NASH?

Retatrutide, developed by Eli Lilly, targets obesity, type 2 diabetes, and liver conditions like metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) including steatosis and NASH (now MASH).[1][2] As a triple receptor agonist, it reduces excess liver fat more effectively than single or dual agents like GLP-1 or GLP-1/GIP agonists.[1] This mechanism shortens the retatrutide NASH reversal timeline to normal liver fat levels compared to standard therapies.

Triple Agonist Mechanism: GLP-1, GIP, and Glucagon Action

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors.[1]

GLP-1 and GIP: These enhance insulin secretion, slow gastric emptying, and suppress appetite, promoting weight loss that indirectly clears liver fat.[1]
Glucagon: Uniquely, it directly stimulates hepatic fat oxidation, elevating beta-hydroxybutyrate—a marker of ketone production from fat breakdown—that peaks by week 24.[1][2]

This synergy results in the fastest liver fat reductions observed in clinical trials.[1]

Understanding MRI-PDFF: The Measurement Tool Behind the Data

Liver fat changes were quantified using magnetic resonance imaging proton density fat fraction (MRI-PDFF), the gold-standard non-invasive method for assessing hepatic steatosis.[2] MRI-PDFF precisely measures fat content as a percentage of liver protons, with <5% indicating normal levels. In retatrutide trials, this imaging captured dose-dependent reductions, enabling accurate tracking of the reversal timeline.[1][2] Unlike ultrasound or biopsy, MRI-PDFF is reproducible and detects changes as small as 1-2%, making it ideal for early-phase studies.[2]

Dosing Schedule: Weekly Injections from 1mg to 12mg

Dosing involves weekly subcutaneous injections with gradual escalation to minimize side effects.[2]

Escalation: Begin at 1-2mg, increasing every 4 weeks to 4mg, 8mg, or 12mg.[2]
Half-life: Approximately 6 days, supporting steady-state exposure.[1][2]

Higher doses correlate with faster milestones on the retatrutide liver steatosis reversal timeline.[2]

NASH Staging: From Simple Steatosis to Advanced Fibrosis

NASH progresses through stages: Stage 0 (steatosis alone), Stage 1 (mild inflammation), up to Stage 3 (bridging fibrosis) and cirrhosis.[4] Retatrutide primarily targets steatosis in Phase 2, with >85% resolution at higher doses, but Phase 3 trials like TRIUMPH-NASH aim at fibrosis endpoints.[3] Early intervention at steatosis stage can prevent progression, underscoring retatrutide's role in halting disease advancement.[4]

Why Retatrutide Excels in Fatty Liver Reduction

Unlike GLP-1 drugs alone, retatrutide's glucagon component directly mobilizes liver triglycerides for oxidation.[1] At 8mg and above, this leads to steatosis resolution in over 85% by week 48, defining its advantage in accelerating NASH reversal timelines.[1][2]

Retatrutide Liver Steatosis NASH Reversal Timeline: Key Milestones

Phase 2 data from the NAFLD subset reveal a rapid retatrutide NASH reversal timeline, measured via MRI-PDFF, with most reductions early and sustained peaks later—outpacing lifestyle methods.[1][2][4]

Weeks 1-24: Rapid Liver Fat Reductions and Beta-Hydroxybutyrate Peaks

Higher doses yield quick results.[1][2]

By week 24: >80% liver fat reduction at 8mg/12mg (P<0.001 vs. placebo); beta-hydroxybutyrate surges from glucagon.[1][2]
Lower doses: 50-60% drops, more tied to weight loss.[1]

Liver volume also decreases dose-dependently by week 24, initiating reversal.[2]

Week 48: Peak Efficacy with Up to 86% Liver Fat Reduction

Dose	Liver Fat Reduction	Normalization Rate (<5%)	Steatosis Resolution
1mg	-51.3%[1][2]	57%[1][2]	N/A
4mg	-59.0%[1][2]	N/A	N/A
8mg	-81.7%[1][2]	89%[1][2]	>85%[1]
12mg	-86.0%[1][2]	93%[1][2]	>85%[1]
Placebo	-4.6%[2]	0%[2]	0%

Table 1: Week 48 outcomes from Phase 2 NAFLD subset (n≈80).[2]

Normalization Rates: 93% Achieve Normal Liver Fat (<5%) at 12mg

Dose-response drives normalization: 93% at 12mg, 89% at 8mg by week 48.[1][2]

Phase 2 Clinical Trial Results: Efficacy Data Breakdown

NCT04881760's NAFLD substudy (obesity patients with NAFLD, n≈80) met liver fat endpoints at 24/48 weeks, outperforming prior therapies.[2]

Dose-Dependent Liver Fat Reductions: 51% to 86% vs. Placebo

All doses superior (P<0.001).[2] Peak: 86% at 12mg; weight loss up to 25.9%.[1][2] See Retatrutide TRIUMPH-1 and TRIUMPH-2 obesity trial results.

Steatosis Resolution: >85% at 8mg and 12mg Doses

85% resolution; ASAT reductions up to 43.5%.[1][2]

Associated Benefits: Liver Volume and ASAT Reductions

Liver volume down by week 24; ASAT 13-44% lower.[2]

Hypothetical Patient Case Studies

Case 1: A 52-year-old with obesity and 15% liver fat started 12mg retatrutide. By week 24, MRI-PDFF showed 82% reduction (to ~3%); normalized by week 48 with 24% weight loss—no adverse liver events.[1][2] Case 2: On 8mg, a patient with mild NASH saw 78% fat drop and steatosis resolution, highlighting dose benefits.[2]

Comparing Retatrutide to Lifestyle Changes and Other Drugs for NASH Reversal

General Steatosis Improvement: 4-12 Weeks with Diet and Exercise

Lifestyle yields ALT/AST improvements in 4-8 weeks; imaging changes in 8-12 weeks with ≥5% weight loss.[4]

NASH and Fibrosis Timelines: 6-24 Months Without Drugs

NASH reversal: 6-12 months (>10% loss); fibrosis 1-2 years.[4]

Retatrutide vs. Other Therapies

Retatrutide surpasses tirzepatide (~8% liver fat drop over 52 weeks).[1] Semaglutide (Phase 2 NASH): ~59% relative reduction but lower normalization (~40%).[7] Resmetirom (FDA-approved for NASH fibrosis, March 2024): Targets THR-β for fat reduction but no weight loss; ~25-30% reductions vs. retatrutide's 86%.[5] Glucagon differentiates retatrutide.[1] See GLP-1 agonists for NASH overview and NASH staging and symptoms.

Safety Profile and Side Effects of Retatrutide in Liver Patients

No hepatotoxicity; enzymes improved.[1][2]

No Hepatotoxicity Signals in NAFLD Subsets

48 weeks: Liver-safe profile.[2]

Common Side Effects Similar to Obesity Trials

Mild-moderate GI (nausea); dose-dependent. See Managing retatrutide dysesthesia and neuropathy risks and Retatrutide side effects and skin tightening prevention.

Monitoring Liver Enzymes: ASAT Improvements Observed

Routine checks; ASAT drops noted.[2]

Clinical Trial Status: Phase 3 and FDA Approval Outlook

Phase 2 complete; Phase 3 advancing.[2][3][6]

Completed Phase 2 (NCT04881760) and Ongoing Phase 3 Trials

TRIUMPH-NASH (NCT05929066): Biopsy-confirmed MASH with fibrosis; 72-96 weeks, ~1,000 patients, endpoints: fibrosis improvement without worsening MASH.[3] TRIUMPH-1 (NCT05882045): Obesity phase 3, liver substudies.[6]

Legal Status: Investigational, Not FDA Approved Yet

Research-only; NDA possible late 2026. Track Retatrutide NDA submission and FDA PDUFA date timeline.

Weight Loss Correlation and Muscle Preservation During Treatment

Weight loss aids (25.9% at 12mg), but glucagon drives direct oxidation.[1][2]

Strategies to Prevent Muscle Loss on Retatrutide

High-protein diet, resistance training. See Retatrutide muscle loss prevention strategies.

Accessing Retatrutide Before FDA Approval: Compounding Options

Investigational; compounding pharmacies operate in gray area—risky due to purity issues.[2] Projections: $1,000-2,000/month in 2026. See Access retatrutide via compounding pharmacies before FDA approval.